Dr. Navin’s group continues to pioneer the developing novel technologies for performing single cell DNA and RNA sequencing, in addition to innovative computational and statistical methods for analyzing the resulting large-scale datasets. These methods are being applied to study cancer evolution in the context of invasion, metastasis and therapy resistance. His laboratory works closely with leading oncologists and pathologist at MD Anderson to translate these technologies into the clinic, where they are poised to make a major impact on reducing the morbidity in human patients.
Dr. Navin has been the recipient of many prestigious awards in recognition of his work, including the Damon-Runyon Innovator Award, AAAS Wachtel Award, ACS Research Scholar Award, Wilson Stone Award, the Randall Innovator Award and the MD Anderson President’s Award for Research Excellence.